A novel therapeutic approach combining human plasma‐derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone

Background and Objectives  Therapy with recombinant Factor VIIa (rFVIIa) for haemophiliacs with inhibitors still has some unresolved problems, such as the requirement for frequent infusions of rFVIIa every 2–3 h to sustain haemostatic activity for an extended time‐period and that the therapeutic dose of rFVIIa is not always predictable. In the present study, we searched for an effective combination of plasma‐derived FVIIa with other blood coagulation factors, and demonstrated that a therapeutic approach combining plasma‐derived FVIIa and Factor X (FX) was more useful for treating haemophiliacs with inhibitors than FVIIa alone.